| 1417 |
National Cancer Institute |
Html |
en |
Stomach (Gastric) Cancer Prevention (PDQ®)–Health Professional Version |
Risk factors for stomach (gastric) cancer include certain health conditions (e.g., atrophic gastritis, pernicious anemia, H. pylori infection), genetic factors (e.g., Li-Fraumeni syndrome), or environmental factors (e.g., diet, smoking). Review the evidence on these and other risk factors and interventions to prevent stomach cancer in this expert-reviewed summary. |
| randomized placebo-controlled trial | 0.595383 |
| gastric adenomatous polyps | 0.679902 |
| experimental animal models | 0.575229 |
| infected family members | 0.578256 |
| antioxidant dietary supplements | 0.574787 |
| H. pylori | 0.663672 |
| annual incidence rates | 0.588818 |
| secondary prevention measures | 0.572741 |
| age-adjusted incidence rate | 0.59463 |
| statistically significant reduction | 0.578799 |
| combined antioxidant groups | 0.572868 |
| H. pylori infection | 0.650947 |
| high H. pylori | 0.585004 |
| family members | 0.581961 |
| gastric cancer mortality | 0.686327 |
| endoscopic resection techniques | 0.578064 |
| placebo group | 0.585452 |
| chemoprevention trial | 0.590009 |
| H. pylori-infected family | 0.583244 |
| Li Fraumeni syndrome | 0.58425 |
| intestinal metaplasia | 0.628781 |
| advanced premalignant lesions | 0.570945 |
| protective effects | 0.575049 |
| low selenium content | 0.586292 |
|
| statistically significant effect | 0.623477 |
| Beta Carotene trial | 0.587524 |
| United States | 0.702911 |
| gastric cancer incidence. | 0.664051 |
| precancerous gastric lesions. | 0.647932 |
| 5-year survival rate | 0.635247 |
| gastric cancer cases | 0.674324 |
| gastric cancers | 0.625749 |
| gastrointestinal cancers | 0.575893 |
| H. pylori-infected people | 0.581367 |
| overall 5-year survival | 0.57409 |
| beta carotene | 0.671292 |
| small randomized trial | 0.598139 |
| gastric cancer | 0.97116 |
| gastric adenocarcinoma. | 0.625249 |
| eradication therapy | 0.572355 |
| Chinese medical journal | 0.572216 |
| vitamin supplementation | 0.570623 |
| statistically significant regression | 0.573687 |
| chronic atrophic gastritis | 0.586209 |
| gastric cancer. | 0.610162 |
| close family members. | 0.576811 |
| family history | 0.58364 |
| steady incidence rates | 0.587586 |
|
CLICK HERE |
| 1460 |
National Cancer Institute |
Html |
en |
Adjustment to Cancer: Anxiety and Distress (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the difficult emotional responses many cancer patients experience. This summary focuses on normal adjustment issues, psychosocial distress, and adjustment disorders. |
| cancer treatment | 0.348496 |
| adjustment disorders | 0.377426 |
| newly diagnosed cancer | 0.338474 |
| palliative care specialist | 0.336033 |
| emotional distress | 0.481089 |
| recurrent breast cancer | 0.355658 |
| ambulatory cancer patients | 0.342576 |
| psychological distress | 0.361971 |
| Japanese cancer patients | 0.3428 |
| Cancer Network Distress | 0.42624 |
| early-stage breast cancer | 0.450601 |
| adult cancer patients | 0.342011 |
| posttreatment distress | 0.33562 |
| health care professionals | 0.348864 |
| normal adjustment | 0.438186 |
| adolescent cancer patients | 0.355821 |
| social support | 0.338806 |
| breast cancer patients | 0.4182 |
| patients | 0.62456 |
| cancer patients | 0.6025 |
| normal adjustment issues | 0.349617 |
| cancer diagnosis | 0.33963 |
| breast cancer survivors | 0.37097 |
| mental disorders | 0.352228 |
| psychosocial distress | 0.487249 |
|
| adjustment | 0.494267 |
| women | 0.328737 |
| distress | 0.685449 |
| psychosocial assessment | 0.364194 |
| study | 0.349859 |
| distress scores | 0.331169 |
| stage breast cancer | 0.326706 |
| breast cancer diagnosis | 0.330404 |
| palliative care | 0.44264 |
| cancer-related life events | 0.334421 |
| life | 0.404419 |
| posttreatment cancer-related distress | 0.396788 |
| general distress indices | 0.342126 |
| primary oncology team | 0.360914 |
| diagnostic criteria | 0.346926 |
| psychosocial assessment interview | 0.338281 |
| Community Cancer Care | 0.328482 |
| advanced cancer | 0.337588 |
| breast cancer | 0.994793 |
| mental disorder | 0.347463 |
| psychological well-being | 0.349655 |
| Psychosocial Distress section | 0.403402 |
| general distress | 0.349587 |
| major depressive disorder | 0.329474 |
|
CLICK HERE |
| 1590 |
National Cancer Institute |
Html |
en |
Adjustment to Cancer: Anxiety and Distress (PDQ®)–Patient Version |
Expert-reviewed information summary about the difficult emotional responses many cancer patients experience. This summary focuses on normal adjustment issues, psychosocial distress, and adjustment disorders. |
| cancer treatment | 0.390955 |
| mental health | 0.376414 |
| emotional distress | 0.342467 |
| mild anxiety | 0.297125 |
| Anxiety disorder—A condition | 0.322854 |
| long-term cancer survivors | 0.290225 |
| following PDQ summaries | 0.289376 |
| PDQ cancer information | 0.401693 |
| clinical trial search | 0.290488 |
| clinical trials | 0.374063 |
| cancer information summary | 0.360243 |
| normal adjustment | 0.315173 |
| Cancer education sessions | 0.292812 |
| patients | 0.858745 |
| cancer diagnosis | 0.420677 |
| mental health problem | 0.344798 |
| symptoms | 0.369957 |
| anxiety | 0.674027 |
| NCI PDQ cancer | 0.318604 |
| cancer survivors | 0.307582 |
| anxiety disorder | 0.421462 |
| great anxiety | 0.289049 |
| problems | 0.310639 |
| distress | 0.498316 |
| treatment | 0.584321 |
|
| cancer prevention | 0.287279 |
| NCI-supported cancer | 0.289072 |
| palliative care | 0.307485 |
| Cancer Information Service | 0.302564 |
| life | 0.319995 |
| generalized anxiety disorder | 0.307665 |
| cancer patients | 0.396085 |
| National Cancer Institute | 0.357347 |
| Cancer Care | 0.313891 |
| adjustment disorder | 0.323889 |
| Palliative Care Editorial | 0.287821 |
| Cancer Care page | 0.291913 |
| Care Editorial Board | 0.290774 |
| anxiety disorders | 0.412812 |
| stressful event | 0.352734 |
| fast heart beat | 0.32985 |
| PDQ summary | 0.441306 |
| intense anxiety | 0.302865 |
| cancer clinical trials | 0.331141 |
| cancer information summaries | 0.300508 |
| comprehensive cancer information | 0.300154 |
| cancer | 0.962959 |
| information | 0.418397 |
| depression | 0.295223 |
|
CLICK HERE |
| 1870 |
National Cancer Institute |
Html |
es |
Tratamiento de los tumores de células germinativas del ovario (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de los tumores de células germinativas del ovario. |
| germ-cell tumors | 0.421459 |
| germ-cell tumors with | 0.411803 |
| Obstet Gynecol | 0.406415 |
| ovarian germ | 0.634072 |
| malignant germ | 0.435096 |
| endodermal sinus tumor | 0.403615 |
| cell tumors treated | 0.404749 |
| Liao SY | 0.410388 |
| Adjuvant therapy | 0.410358 |
| Gershenson DM | 0.467949 |
| Current therapy | 0.403318 |
| Williams SD | 0.494559 |
| tumores malignos mixtos | 0.404882 |
| Hacker NF | 0.402853 |
| Instituto Nacional | 0.403668 |
| high-dose chemotherapy | 0.403104 |
| or etoposide | 0.404727 |
| DiSaia PJ | 0.408704 |
| Moore DH | 0.407371 |
| University Medical Center | 0.403543 |
| quimioterapia postoperatoria | 0.403765 |
| Gynecol Oncol | 0.453558 |
| pacientes jóvenes | 0.408368 |
| lavados peritoneales | 0.410402 |
| New York University | 0.403494 |
|
| Icb Tumor | 0.403092 |
| gynecologic oncology group | 0.703201 |
| Blessing JA | 0.51199 |
| Birch R | 0.404259 |
| estadio iv | 0.424378 |
| Einhorn LH | 0.40484 |
| Dembo AJ | 0.402909 |
| estadio ia | 0.408575 |
| ovary with | 0.410468 |
| Morris M | 0.407706 |
| with advanced germ | 0.403782 |
| IIIa Tumor | 0.403067 |
| York University Medical | 0.403528 |
| Intern Med | 0.411687 |
| second-look laparotomy | 0.431921 |
| Clin Oncol | 0.539728 |
| estadio iii | 0.41476 |
| cell tumors using | 0.405334 |
| tumor macroscópico | 0.402814 |
| Oncology Group Study | 0.403519 |
| germ cell tumors | 0.985883 |
| histerectomÃa abdominal | 0.412918 |
| Cangir A | 0.408111 |
| cell tumors with | 0.436879 |
|
CLICK HERE |
| 1938 |
National Cancer Institute |
Html |
es |
Grados de comprobación científica de los estudios sobre el tratamiento del cáncer en adultos y niños (PDQ®)–Versión para profesionales de salud |
Información sobre cómo evaluar la solidez de los datos probatorios que se obtienen de diferentes clases de estudios sobre el tratamiento del cáncer. |
| Visuals Online | 0.667636 |
| Physician Data Query | 0.729238 |
| Benhaddad A | 0.68991 |
| oro —el ensayo | 0.814208 |
| estadÃstico kappa | 0.695883 |
| valoración indirectos | 0.767699 |
| hipótesis prospectivas explÃcitas | 0.790489 |
| amputación vs | 0.700012 |
| único diseño | 0.677496 |
| marcadores indirectos | 0.945889 |
|
| National Cancer Institute | 0.71653 |
| alto efectos | 0.677847 |
| subsequent large randomized | 0.778241 |
| controlled trials | 0.698624 |
| Grégoire G | 0.694845 |
| siguientes riesgos | 0.670189 |
| valores lÃmite | 0.703358 |
| Instituto Nacional | 0.973244 |
| historia clÃnica | 0.690891 |
|
CLICK HERE |
| 1989 |
National Cancer Institute |
Html |
es |
Cuidados médicos de apoyo en niños (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca de la peculiaridad de los asuntos que surgen durante y después del tratamiento en los niños con cáncer, y como sobrevivientes adultos de cáncer. |
| etapa final | 0.974283 |
| posibles efectos tardÃos | 0.445113 |
| células madre | 0.448459 |
| adultos jóvenes | 0.631616 |
| personas jóvenes | 0.478657 |
| posibles tratamientos | 0.424654 |
| siguientes aspectos | 0.421705 |
| cáncer causa estrés | 0.501532 |
| apoyo social escaso | 0.437899 |
| siguientes tipos | 0.415041 |
| largo plazo | 0.418906 |
| efectos tardÃos | 0.530812 |
| familia reaccionarán | 0.418853 |
| National Cancer Institute | 0.415958 |
| siguientes riesgos | 0.411551 |
|
| siguientes maneras | 0.446878 |
| Instituto Nacional | 0.427962 |
| sÃntomasEl trastorno | 0.423462 |
| Cuidado paliativo | 0.412419 |
| distintos miembros | 0.413316 |
| tratamiento ayuda | 0.457106 |
| suicidioUn número | 0.419685 |
| siguientes efectos | 0.419968 |
| posibles efectos | 0.465562 |
| Physician Data Query | 0.458553 |
| sistema nervioso central | 0.433857 |
| mayores probabilidades | 0.421125 |
| Estados Unidos | 0.416849 |
| mejores tratamientos | 0.417691 |
|
CLICK HERE |
| 3444 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de cavidad oral y orofaringe (PDQ®)–Versión para profesionales de salud |
Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de cavidad oral y orofaringe. |
| Ramadas K | 0.326456 |
| Sankaranarayanan R | 0.337876 |
| accessed march | 0.331249 |
| Zhang L | 0.310727 |
| Clinical Preventive Services | 0.308765 |
| Interim results from | 0.307724 |
| Sin embargo | 0.381657 |
| Kerr AR | 0.312561 |
| American Cancer Society | 0.427439 |
| Early findings from | 0.308051 |
| CA Cancer | 0.323169 |
| cluster randomized controlled | 0.308479 |
| oral pre-malignant | 0.326412 |
| oral cancer | 0.913191 |
| Preventive Services Task | 0.376173 |
| Instituto Nacional | 0.317765 |
| Cancer Res | 0.323621 |
| Human papillomavirus infection | 0.307515 |
| PDQ Exámenes | 0.32226 |
| oral cancer screening | 0.566684 |
| Estados Unidos | 0.310609 |
| Morton TH Jr | 0.307383 |
| Morton TH | 0.311837 |
| Epstein JB | 0.323025 |
| Database Syst Rev | 0.307163 |
|
| visual screening | 0.315772 |
| screening with | 0.315479 |
| upper aerodigestive tract | 0.307566 |
| SEER Cancer Statistics | 0.324889 |
| Cancer Society guidelines | 0.325639 |
| Trivandrum Oral Cancer | 0.343561 |
| carcinoma versus lesiones | 0.311231 |
| Jacob BJ | 0.31089 |
| potentially malignant disorders | 0.308445 |
| Cancer Facts | 0.324242 |
| Long term effect | 0.3078 |
| adjacent to clinically | 0.307949 |
| Oral Oncol | 0.526329 |
| oral verrucous | 0.325426 |
| National Cancer Institute | 0.351683 |
| center grapples with | 0.307601 |
| Oral Pathol Med | 0.361585 |
| Screening Study Group | 0.316915 |
| Am Dent Assoc | 0.308416 |
| Services Task Force | 0.375429 |
| Fluorescence visualization detection | 0.308258 |
| detección versus atención | 0.319469 |
| Brief Evidence Update | 0.307856 |
| Poh CF | 0.312257 |
|
CLICK HERE |
| 15486 |
National Cancer Institute |
Html |
es |
Delirio |
¿Qué es delirio? Delirio es un estado mental confuse. Se explican las causas de delirio, formas de tratarlo y preguntas para hacer al doctor. |
| delirio hiperactivo | 0.974791 |
|
|
CLICK HERE |
| 15633 |
National Cancer Institute |
Html |
en |
Step 1: Application Development & Submission |
There are nine research grant application types, each with specific procedures. Learn more about developing, submitting, and tracking a cancer research grant application. |
| small project application | 0.562018 |
| grant application types | 0.615791 |
| Funding Opportunity Announcement | 0.657432 |
| grant applications | 0.709584 |
| institution business official | 0.474155 |
| Grants.gov Tracking Number | 0.523008 |
| ongoing extramural activity | 0.49934 |
| NIH’s Application | 0.521892 |
| Grants.gov Registration | 0.46434 |
| application requirements | 0.476818 |
| Administrative Supplement Request | 0.466071 |
| specific receipt date | 0.531978 |
| grant type | 0.487204 |
| specific IC program | 0.505666 |
| peer review processes | 0.498397 |
| prior approval | 0.560178 |
| well-defined scientific area | 0.49086 |
| eRA Commons | 0.962876 |
| receipt date | 0.604332 |
| Electronic grant applications | 0.606906 |
| NIH Guide | 0.481058 |
| program announcement | 0.579666 |
|
| NCI Grant Policies | 0.586226 |
| sam registration | 0.473955 |
| scientific peer review | 0.497797 |
| Small Business Innovation | 0.484684 |
| application status changes—the | 0.535723 |
| NCI Funding Opportunities | 0.538102 |
| NIH | 0.523095 |
| recent budget project | 0.476777 |
| Scientific Review Group | 0.50345 |
| NCI RFA | 0.467797 |
| application submission deadline | 0.550381 |
| grant support | 0.469498 |
| important application basics | 0.5838 |
| strong application | 0.469473 |
| application | 0.872468 |
| application cycles | 0.489855 |
| final assembled application | 0.53419 |
| additional prior approval | 0.492691 |
| grant application | 0.737304 |
| standing receipt date | 0.526741 |
| Small Business Technology | 0.489507 |
|
CLICK HERE |
| 16857 |
National Cancer Institute |
Html |
en |
Prior Approval Requests |
null |
| recipient institution | 0.428349 |
| current policies | 0.408224 |
| NoA | 0.327733 |
| NIH recipients | 0.49032 |
| enforcement action | 0.408587 |
| latitude | 0.326586 |
| prior approval requests | 0.721397 |
| specific prior approval | 0.686294 |
| grants management specialist | 0.645519 |
| certain degree | 0.434218 |
| copies | 0.318206 |
| prior approval authority | 0.69999 |
| terms | 0.318069 |
| prior approval | 0.984844 |
| unanticipated requirements | 0.40335 |
| total costs | 0.405045 |
| Questions | 0.317851 |
| makes certain budget | 0.539233 |
| NIH Grants Policy | 0.559485 |
| limits | 0.321806 |
| email | 0.319573 |
| recipient’s discretion | 0.470347 |
| cc | 0.322104 |
|
| termination | 0.321773 |
| Circumstances | 0.323427 |
| types | 0.321678 |
| cases | 0.320114 |
| subject line | 0.413724 |
| budget categories | 0.540205 |
| Statement | 0.318087 |
| GMO | 0.360575 |
| disallowance | 0.318052 |
| grants management officer | 0.531732 |
| proposed change | 0.416195 |
| agency authority | 0.407763 |
| NCI program director | 0.515619 |
| unauthorized officials | 0.411596 |
| PD/PI | 0.318695 |
| undertakes particular activities | 0.523 |
| expenditures | 0.324868 |
| response | 0.318742 |
| post-award changes | 0.427573 |
| grant number | 0.410914 |
| unanticipated needs | 0.427883 |
| responses | 0.319676 |
| risk | 0.318261 |
|
CLICK HERE |